Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $116,242.56 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the transaction, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, May 18th, Richard Nolan Townsend sold 3,342 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.06, for a total value of $16,910.52.
• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.69, for a total value of $312,950.00.

Lexeo Therapeutics Price Performance

LXEO opened at $4.69 on Friday. The business has a fifty day simple moving average of $5.06 and a 200 day simple moving average of $6.58. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The company has a market capitalization of $368.26 million, a PE ratio of -3.23 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Equities analysts anticipate that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in Lexeo Therapeutics in the fourth quarter valued at approximately $49,650,000. Paradigm Biocapital Advisors LP acquired a new position in Lexeo Therapeutics during the fourth quarter worth about $47,299,000. Balyasny Asset Management L.P. bought a new position in shares of Lexeo Therapeutics in the second quarter worth about $16,117,000. Avoro Capital Advisors LLC bought a new position in shares of Lexeo Therapeutics in the fourth quarter worth about $32,769,000. Finally, State Street Corp boosted its stake in shares of Lexeo Therapeutics by 485.1% in the 4th quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after purchasing an additional 2,642,877 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. JPMorgan Chase & Co. dropped their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Finally, Chardan Capital reissued a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.